Please login to the form below

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London. Roy is a seasoned market research professional with over 20 years’ experience in healthcare research and consulting. He joins the US Division of the company as an expert quantitative researcher, bringing with him much experience in a breadth of different research techniques.

Previously, Roy was a Partner at Hall & Partners, co-managing a team of 40 researchers. He began his career in market research at BMRB and Research International, moving into pharmaceutical market research while at Millward Brown, where he was one of the founding members of the Healthcare Practice.

Senior Director, Andrew Stokes said of his appointment, “I am delighted to welcome Roy to the company. We have a dynamic group of researchers in the London office and Roy’s quantitative experience adds another layer of expertise within the group.”

Founding Director Mary Assimakopoulos added, “We are very pleased that Roy has chosen to join Research Partnership. His specialist expertise will be a great asset to the Quantitative Centre of Excellence, which aims to stay at the forefront of best practice and innovation.”

26th March 2021

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

RP Investigates - Virtual Q&A session:
Living with Lupus
Research Partnership
Webcast:
Demand assessment
Research Partnership
White paper:
Are we prepared for the influx of CAR-Ts?
Research Partnership
New syndicated patient report -
Living with Lupus US
Research Partnership
Video:
Emotion AI
Research Partnership
Report:
Mexico’s drug market access landscape shake-up: What does it mean for pharma?
Research Partnership